Diabetic Nephropathies: Clinical Trials

140 trials for Diabetic Nephropathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

96 completed, 12 unknown, 10 recruiting, 10 terminated. 140 Phase 2, 15 Phase 1, 15 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2140Completed 96, Unknown 12, Recruiting 10, Terminated 10, Active not recruiting 4, Withdrawn 4, Not yet recruiting 3, Suspended 1
Phase 115Completed 9, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 315Completed 9, Unknown 5, Terminated 1

Follow Diabetic Nephropathies: new trials by email Literature Review of Diabetic Nephropathies trials Research Report on Diabetic Nephropathies

Trials (filtered) newest first · largest first

All 140 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin - Type 1 Diabetes Mellitus With Diabetic Nephropathy
Phase 2Not yet recruitingUniversity Medical Center Groningen362027-01-012026-10-20
Mesenchymal Stem Cells for Chronic Kidney Diseases
0.9% sodium chloride, MSCs - Kidney Disease, Chronic, Diabetic Kidney Disease (DKD)
Phase 1 / Phase 2Not yet recruitingThe First Affiliated Hospital of Air Force Medical University322026-11-012026-11-16
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
Umbilical Cord Mesenchymal Stem Cells - Diabetic Nephropathy Type 2
Phase 1 / Phase 2RecruitingPT. Prodia Stem Cell Indonesia102026-07-012026-02-09
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
ALN-ANG3, Evinacumab, Placebo - Diabetic Kidney Disease (DKD)
Phase 2RecruitingRegeneron Pharmaceuticals1952026-01-092026-10-27
Formoterol in Diabetes
Formoterol furmarate (20 μg) - Diabetic Nephropathies, Diabetic Kidney Disease
Phase 2RecruitingMedical University of South Carolina1202025-12-012026-02-05
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen - Diabetic Kidney Disease (DKD), Type 2 Diabetes
Phase 2Active not recruitingBeijing University of Chinese Medicine152025-10-202026-11-02
Lactoferrin Supplementation in Diabetic Nephropathy
Lactoferrin, Antidiabetic, Placebo - Diabetic Nephropathy
Phase 2RecruitingAin Shams University602025-08-012026-08-14
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
2HPβCD - Diabetic Kidney Disease
Phase 2WithdrawnZyVersa Therapeutics, Inc.2025-06-112025-11-25
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
Amimestrocel - Diabetic Kidney Disease (DKD)
Phase 2RecruitingChinese PLA General Hospital1202025-06-092026-07-14
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
Isuzinaxib, Placebo - Diabetic Kidney Disease (DKD)
Phase 2RecruitingAptabio Therapeutics, Inc.1862025-05-262025-07-18
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
Sotagliflozin, Placebo - Nephropathy, Diabetic Nephropathies
Phase 2Not yet recruitingSteno Diabetes Center Copenhagen692025-02-012025-01-27
SGLT2 Adjunct in T1D
Empagliflozin (EMPA), Placebo - Type 1 Diabetes, Nephropathy, Diabetic
Phase 2 / Phase 3CompletedAin Shams University862024-11-202026-05-18
Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy.
Oligo-fucoidan, Fucoxanthin, L-carnitine Formula, Zinc yeast (FFL) - Diabetic Kidney Disease (DKD)
Phase 2CompletedTaipei Medical University WanFang Hospital632024-11-062026-09-04
The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.
R3R01, Placebo - Diabetic Kidney Disease
Phase 2RecruitingRiver 3 Renal Corp.602024-10-102026-09-23
Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Vinpocetine, Standard Therapy, Placebo - Diabetic Kidney Disease, Diabetic Nephropathies
Phase 2 / Phase 3UnknownAin Shams University642024-07-102024-07-11
Study of WAL0921 in Patients With Glomerular Kidney Diseases
WAL0921, Placebo - Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Phase 2RecruitingWalden Biosciences962024-07-022026-08-03
Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes
Placebo, HRS-7535 - Diabetic Kidney Disease, Type 2 Diabetes
Phase 2CompletedShandong Suncadia Medicine Co., Ltd.2812024-06-212026-01-05
Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease
Dendritic cell immunotherapy - Diabetic Kidney Disease (DKD)
Phase 1 / Phase 2Active not recruitingPT. JES Kasih Nusantara Sejahterah802024-05-012025-12-05
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Semaglutide, Placebo - Diabetic Kidney Disease, Type 1 Diabetes
Phase 2RecruitingUniversity of Washington602024-04-052026-06-02
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD - Chronic Kidney Disease
Phase 2CompletedMineralys Therapeutics Inc.602023-12-142026-06-03

Showing 20 of 140. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 2 (31)  ·  Renal Insufficiency, Chronic (26)  ·  Diabetes Mellitus (23)  ·  Kidney Diseases (18)  ·  Proteinuria (14)  ·  Albuminuria (12)  ·  Diabetes Mellitus, Type 1 (11)  ·  Diabetes Complications (7)  ·  Hypertension (7)  ·  Glomerulonephritis, IGA (5)  ·  Endocrine System Diseases (3)  ·  Kidney Failure, Chronic (3)  ·  Urologic Diseases (3)  ·  Glomerulonephritis (2)

Broader conditions

Female Urogenital Diseases (140)  ·  Female Urogenital Diseases and Pregnancy Complications (140)  ·  Male Urogenital Diseases (140)  ·  Urogenital Diseases (140)  ·  Endocrine System Diseases (137)  ·  Urologic Diseases (137)  ·  Diabetes Complications (133)  ·  Kidney Diseases (122)  ·  Diabetes Mellitus (117)  ·  Nutritional and Metabolic Diseases (58)  ·  Glucose Metabolism Disorders (56)  ·  Metabolic Diseases (56)  ·  Pathological Conditions, Signs and Symptoms (47)  ·  Pathologic Processes (30)  ·  Disease Attributes (29)

Interventions

Atrasentan (6)  ·  dapagliflozin (5)  ·  empagliflozin (4)  ·  Acetylcysteine (3)  ·  Hypoglycemic Agents (3)  ·  Spironolactone (3)  ·  Standard of Care (3)  ·  bardoxolone methyl (3)  ·  finerenone (3)  ·  p-Aminohippuric Acid (3)  ·  pyridoxamine dihydrochloride (3)  ·  semaglutide (3)  ·  CCX140-B (2)  ·  Cholecalciferol (2)  ·  Colchicine (2)

Sponsors

Tanabe Pharma Corporation (6)  ·  University of Colorado, Denver (5)  ·  AbbVie (prior sponsor, Abbott) (4)  ·  Ain Shams University (4)  ·  AstraZeneca (4)  ·  Bayer (4)  ·  University of Washington (4)  ·  Biogen (3)  ·  Eli Lilly and Company (3)  ·  Novartis Pharmaceuticals (3)  ·  Pfizer (3)  ·  Shiraz University of Medical Sciences (3)  ·  Amgen (2)  ·  Aptabio Therapeutics, Inc. (2)  ·  BioStratum (2)

Countries

United States (60)  ·  Canada (18)  ·  Japan (17)  ·  Australia (15)  ·  Denmark (15)  ·  Germany (12)  ·  Italy (12)  ·  United Kingdom (12)  ·  South Korea (11)  ·  Spain (11)  ·  Hungary (10)  ·  Poland (10)  ·  Netherlands (9)  ·  China (8)  ·  Czechia (8)

Top investigators

Petter Bjornstad, MD (3)  ·  Blai Coll, MD (2)  ·  Connie L Davis, MD (2)  ·  Hiddo J Lambers Heerspink, PhD, PharmD (2)  ·  Jamshid Roozbeh, MD (2)  ·  Masaomi Nangaku, Professor (2)  ·  Paolo Fanti, MD (2)  ·  Thorsten P Degenhardt, Ph.D. (2)

Results publications

PMID 33107592, PMID 41805697, PMID 28756065, PMID 37916745, PMID 23986513, PMID 31583611, PMID 32974732, PMID 38537621, PMID 11238785, PMID 11304102, PMID 11565517, PMID 11565518, PMID 11832527, PMID 12684357, PMID 15273542, PMID 15380496, PMID 15632335, PMID 16120818, PMID 16188903, PMID 18430778, PMID 18435772, PMID 18525041, PMID 18701613, PMID 19420913, PMID 19808241, PMID 19954692, PMID 20150934, PMID 20693353, PMID 20700413, PMID 20876408, PMID 21055801, PMID 21270268, PMID 21602457, PMID 21693741, PMID 21699484, PMID 21931075, PMID 22187472, PMID 22461535, PMID 22723580, PMID 22770926, PMID 23288372, PMID 23333585, PMID 23362314, PMID 23787544, PMID 23804455, PMID 24149519, PMID 24356416, PMID 24622263, PMID 24722445, PMID 25352176

NIH funding

2016 (2), 2018 (2), R21AT004490 (2), 1KL2RR025015-01 (1), 2004 (1), 2005 (1), 2014 (1), 2017 (1), 2019 (1), I01CX000264 (1), P30DK017047 (1), R01DK063017 (1), R21AT002367 (1)